Takeda weighs bidders for drug portfolio sale — 4 insights

Takeda is looking to trim debt from its $59 billion purchase of Shire by selling portions of its drug portfolio in western Europe, Reuters reports.

What you should know:

1. Takeda wants to make 1.5 billion euros — $1.68 billion — from the sale.

2. The portfolio consists of over-the-counter and prescription medications where Takeda's patent has expired. Despite that, the portfolio has an EBITDA of around 160 million euros ($179.6 million).

3. Takeda retained the services of JPMorgan to find a buyer.

4. Takeda's acquisition of Shire put the company $52.73 billion in debt. To lower this, Takeda is attempting to sell $10 billion in assets.

More articles on surgery centers: 
6 surgery centers achieving total joint milestones
Regent Surgical Health, Conformis partner to cut ASC joint replacement costs
ASC total joint program bundles, vendors & more — 3 insights from an administrator

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers